Psoriasis Clinical Trial
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).
NOTE: Detailed Description : data not entered
Patient must have participated in core study CAIN457F2304, and must have completed the entire treatment period up to and including Week 104.
Patients must be deemed by the investigator to benefit from continued secukinumab therapy.
Plans for administration of live vaccines during the extension study period.
Any patient taking other concomitant biologic immunomodulating agent(s) except secukinumab.
Any patient who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms.
All other protocol related inclusion/exclusion criteria will apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 23 Locations for this study
Boise Idaho, 83702, United States
Cincinnati Ohio, 45229, United States
Portland Oregon, 97232, United States
Bruxelles , 1200, Belgium
Gent , 9000, Belgium
Freiburg , 79106, Germany
Hamburg , 22081, Germany
Saint Augustin , 53757, Germany
Genova GE, 16147, Italy
Napoli , 80131, Italy
Krakow , 31503, Poland
Ekaterinburg , 62014, Russian Federation
Moscow , 11999, Russian Federation
Saint-Petersburg , 19410, Russian Federation
Voronezh , 39403, Russian Federation
Panorama Western Cape, 7500, South Africa
Cape Town , 7925, South Africa
Santiago De Compostela Galicia, 15706, Spain
Valencia , 46026, Spain
Istanbul Halkali, 34303, Turkey
Istanbul TUR, 34098, Turkey
Ankara , 06100, Turkey
Istanbul , 34390, Turkey
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.